Cardioprotective Effects of HO-1-Loaded Collagen-Targeted Phase Change Nanoparticles on Cardiomyocytes Following Acute Myocardial Infarction
Acute myocardial infarction (MI) is a major cause of death worldwide. This study utilized collagen-targeted phase change material (PCM) nanoparticles (NPs) to co-encapsulate HO-1 and explored the efficacy of composite PCM NPs on cardiomyocyte progression and development of MI. In this study, we enrolled 32 acute MI patients and 32 healthy participants, and ELISA assay was used to assess the content of creatine kinase isoenzyme (CK-MB). Mice with MI received tail vein administration of HO-1-loaded PCM NPs, followed by RT-qPCR detection of expressions of hypoxia-reoxygenation related genes (SpA, SpB, SpC, Occludin, KGF, and CK18). Patients with acute MI had a higher level of CK-MB. Treatment with HO-1-loaded collagen-targeted PCM NPs decreased expressions of SpA, SpB, SpC, Occludin, KGF, and CK18, facilitating repair of damaged tissues. Of note, NPs loaded with siRNA HO-1 up-regulated the expression of these genes. Collagen-targeted PCM NPs carrying HO-1 effectively promoted the repair of myocardial cells and relieved MI through down-regulation of hypoxia-reoxygenation related genes, which may enhance prevention and treatment for acute MI.